INTRODUCTION: Highly effective antiretroviral therapy in the last decade has increased the survival rates of HIV-positive patients, yielding a greater number of HIV patients suffering from liver-related disease. Liver transplantation (LT) is the only curative treatment for end-stage liver disease (ESLD) associated or not with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: From June 2003 to September 2010, 23 patients underwent cadaveric donor LT for ESLD at our institution. Inclusion criteria followed the Italian Protocol for LT in HIV-positive patients. Immunosuppressive regimens were based on cyclosporine or tacrolimus, eventually switched to Rapamycin. RESULTS: The median CD4 T-cell count was 275/mmc (range=119-924). All patients were affected by ESLD, which was associated with HCC in 14 cases. Ten patients were within the Milan criteria and four patients exceeded them but were within the San Francisco criteria. Conversion from calcineurin inhibitors (CNI) to rapamycin occurred in ten cases. Hepatitis C virus (HCV) recurrence occurred in 13/21 HCV-positive patients. Acute cellular rejection occurred in eight patients with one developing chronic cellular rejection. Overall patient and graft survivals at 80 months were 50% and 45% respectively. DISCUSSION: LT in HIV-positive patients is a feasible procedure, even if in our experience was burdened by a greater incidence of complications including HCV recurrence and infection compared with HIV-negative patients.
INTRODUCTION: Highly effective antiretroviral therapy in the last decade has increased the survival rates of HIV-positivepatients, yielding a greater number of HIV patients suffering from liver-related disease. Liver transplantation (LT) is the only curative treatment for end-stage liver disease (ESLD) associated or not with hepatocellular carcinoma (HCC). PATIENTS AND METHODS: From June 2003 to September 2010, 23 patients underwent cadaveric donor LT for ESLD at our institution. Inclusion criteria followed the Italian Protocol for LT in HIV-positivepatients. Immunosuppressive regimens were based on cyclosporine or tacrolimus, eventually switched to Rapamycin. RESULTS: The median CD4 T-cell count was 275/mmc (range=119-924). All patients were affected by ESLD, which was associated with HCC in 14 cases. Ten patients were within the Milan criteria and four patients exceeded them but were within the San Francisco criteria. Conversion from calcineurin inhibitors (CNI) to rapamycin occurred in ten cases. Hepatitis C virus (HCV) recurrence occurred in 13/21 HCV-positive patients. Acute cellular rejection occurred in eight patients with one developing chronic cellular rejection. Overall patient and graft survivals at 80 months were 50% and 45% respectively. DISCUSSION: LT in HIV-positivepatients is a feasible procedure, even if in our experience was burdened by a greater incidence of complications including HCV recurrence and infection compared with HIV-negative patients.
Authors: Michelle E Roland; Burc Barin; Shirish Huprikar; Barbara Murphy; Douglas W Hanto; Emily Blumberg; Kim Olthoff; David Simon; William D Hardy; George Beatty; Peter G Stock Journal: AIDS Date: 2016-01-28 Impact factor: 4.177
Authors: Giovanni Guaraldi; Giovanni Dolci; Stefano Zona; Giuseppe Tarantino; Valentina Serra; Roberto Ballarin; Erica Franceschini; Mauro Codeluppi; Thomas D Brothers; Cristina Mussini; Fabrizio Di Benedetto Journal: AIDS Res Ther Date: 2017-08-05 Impact factor: 2.250
Authors: Benjamin D Varco-Merth; William Brantley; Alejandra Marenco; Derick D Duell; Devin N Fachko; Brian Richardson; Kathleen Busman-Sahay; Danica Shao; Walter Flores; Kathleen Engelman; Yoshinori Fukazawa; Scott W Wong; Rebecca L Skalsky; Jeremy Smedley; Michael K Axthelm; Jeffrey D Lifson; Jacob D Estes; Paul T Edlefsen; Louis J Picker; Cheryl Ma Cameron; Timothy J Henrich; Afam A Okoye Journal: J Clin Invest Date: 2022-05-16 Impact factor: 19.456